Figure 6.

In vivo tumor growth inhibition for compound 28 in the TNBC model CTG-1017. Athymic Nude-Foxn1^nu mice bearing established subcutaneous PDX tumors (mean starting tumor volume of 157 mm³) were treated with vehicle (saline), 28, or SOC chemotherapeutics (cisplatin and gemcitabine). Vehicle and 28 at 60 mg/kg were administered orally using an intermittent dosing schedule of 3-days on, 4-days off for up to 4 weekly cycles (day 30 TGI = 82%, p = 0.0001 vs vehicle). SOC were administered as follows: cisplatin 5 mg/kg i.p. Q7D×3 + gemcitabine 100 mg/kg i.p. Q7D×3. The corresponding mean body weight over time graph can be found in the Supporting Information.